Literature DB >> 30681031

Nonopioid versus opioid agents for chronic neuropathic pain, rheumatoid arthritis pain, cancer pain and low back pain.

Selaiman A Noori1, Rohit Aiyer2, James Yu3, Robert S White2, Neel Mehta2, Amitabh Gulati4.   

Abstract

Chronic pain continues to be a major health issue throughout the world and a huge economic burden for nations around the world. While the use of opioids does have risks, they are still widely used by clinicians as a treatment option for various chronic pain conditions. This review explores and compares the efficacy and safety of opioid and nonopioid agents for the following commonly encountered chronic pain conditions: neuropathic pain, rheumatoid arthritis joint pain, cancer pain and low back pain. Our findings demonstrate that while there are several nonopioid pharmacologic options that are clinically effective, opioids maintain a role in the treatment of certain chronic pain conditions and should continue to have an important place in the armamentarium of clinicians.

Entities:  

Keywords:  cancer pain; inflammatory pain; low back pain; neuropathic pain; opioids; rheumatologic pain

Mesh:

Substances:

Year:  2019        PMID: 30681031     DOI: 10.2217/pmt-2018-0052

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  8 in total

1.  Medical Use of Long-term Extended-release Opioid Analgesics in Commercially Insured Adults in the United States.

Authors:  Jessica C Young; Michele Jonsson Funk; Nabarun Dasgupta
Journal:  Pain Med       Date:  2020-04-01       Impact factor: 3.750

Review 2.  Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review.

Authors:  Gustavo Marinho Miranda; Vitória Ohana Ramos E Santos; Jonatas Reis Bessa; Yanna C F Teles; Setondji Cocou Modeste Alexandre Yahouédéhou; Marilda Souza Goncalves; Jaime Ribeiro-Filho
Journal:  Biomolecules       Date:  2021-02-27

3.  Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial.

Authors:  Sofia Pazmino; Annelies Boonen; Diederik De Cock; Veerle Stouten; Johan Joly; Delphine Bertrand; René Westhovens; Patrick Verschueren
Journal:  RMD Open       Date:  2021-05

4.  Impact of Nerve Surgery on Opioid and Medication Use in Patients with Chronic Nerve Injuries.

Authors:  John M Felder; Ivica Ducic
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-09-07

5.  Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies.

Authors:  Michael Camilleri; Martin Hale; Bart Morlion; Jan Tack; Lynn Webster; James Wild
Journal:  J Pain Res       Date:  2021-07-16       Impact factor: 3.133

6.  Discovery of Novel µ-Opioid Receptor Inverse Agonist from a Combinatorial Library of Tetrapeptides through Structure-Based Virtual Screening.

Authors:  Giulio Poli; Marilisa Pia Dimmito; Adriano Mollica; Gokhan Zengin; Sandor Benyhe; Ferenc Zador; Azzurra Stefanucci
Journal:  Molecules       Date:  2019-10-27       Impact factor: 4.411

7.  A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.

Authors:  Lynn R Webster; Martin E Hale; Tadaaki Yamada; James E Wild
Journal:  J Pain Res       Date:  2020-03-24       Impact factor: 3.133

8.  Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.

Authors:  James Wild; Lynn Webster; Tadaaki Yamada; Martin Hale
Journal:  Drugs Aging       Date:  2020-04       Impact factor: 4.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.